Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications.
Illumina and Agendia plan to develop new tests to enhance the care and management of breast cancer patients, utilizing the Illumina MiSeq™Dx sequencing platform to expand the range of gene panels available for solid tumor analysis. The company expects its flagship test, MammaPrint®, which is FDA-cleared and currently offered via Agendia’s central laboratory, will be the first decentralized NGS-based breast cancer recurrence risk test cleared by the FDA.
“This partnership represents a major step in Agendia’s integration of NGS technologies and brings us even closer to our promise of providing crucial genomic information to physicians and their patients to guide care at every single step in a patient’s treatment journey,” said Mark Straley, Chief Executive Officer of Agendia. “We believe our current FDA-cleared, broadly reimbursed MammaPrint test provides the perfect foundation for incorporation with Illumina’s MiSeqDx platform. Together, we plan to expand what is possible in breast cancer care and ensure that the essential insights that come from genomic testing are delivered to patients around the world.”
Illumina’s robust diagnostic NGS product portfolio, including the MiSeq™Dx platform, covers a broad range of clinical applications designed for a variety of clinical lab settings. As NGS testing becomes more integrated in routine patient care, Illumina is committed to providing clinical solutions, through both products and partnerships, that enable the diagnosis and management of human diseases.
Agendia’s proprietary testing solutions empower physicians to more accurately diagnose the disease drivers and predict the progression of a woman’s breast cancer. The company’s scientific approach provides a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to personalize treatment. The company believes the decentralized MammaPrint NGS test, developed on the Illumina MiSeq™Dx platform, will enable major clinical hospitals worldwide to offer the clinical utility and benefits of MammaPrint to their physicians and patients in-house. In addition, the MammaPrint NGS test will leverage nearly two decades of clinical evidence drawn from 30 clinical studies featuring over 30,000 patients with breast cancer, as well as a 15-year history of FDA clearance, top tier medical society guideline inclusion, and well-established and unique CPT codes for broad reimbursement.
“We are pleased to partner with Agendia, with its deep expertise in genomic testing in breast cancer, to expand the reach of NGS-based genomic testing in cancer care,” said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. “We believe enabling in-house clinical testing will strengthen the knowledge of the healthcare network, reduce turnaround times, and ultimately better support more patients with improved guidance on care pathways.”
Agendia is a mission-driven, commercial stage company focused on enabling state-of-the-art decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Westwicke/ICR Healthcare PR
Westwicke/ICR Healthcare PR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tech Mahindra Bets Big on Digitally Transforming Insurance Industry; Acquires Com Tec Co IT Ltd and Invests in Two Leading InsurTech Platforms17.1.2022 17:52:00 EET | Press release
Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services & solutions, today announced 100% acquisition of Com Tec Co IT Ltd (CTC) for €310 million including earnouts and synergy linked payouts. CTC is an IT solutions and service provider serving the insurance and financial services industries with development centres in Latvia and Belarus. The acquisition will enable Tech Mahindra to tap onto the potential industry disruption in the Insurance sector, expand its offerings to high-end digital engineering services for some of the largest insurance, reinsurance and financial services organizations globally and scale its nearshore delivery presence. Tech Mahindra is also investing a cumulative amount of €20 million, in SWFT and Surance, for a 25% ownership in each of these two InsurTech ventures funded by the same founding group as CTC. SWFT is a SaaS-based digital customer engagement platform. It offers multiple functionalities for insur
Toshiba Appoints Andrew McDaniel to Lead Its European Retail Business17.1.2022 16:00:00 EET | Press release
Toshiba Global Commerce Solutions today announced the appointment of technology and business innovator Andrew McDaniel as managing director and senior vice president of Europe effective January 15, 2022. Based in Ireland, McDaniel will assume leadership of all European operations, reporting to Rance Poehler, global president and CEO, Toshiba Global Commerce Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005027/en/ Andrew McDaniel, Managing Director and Senior Vice President of Europe, Toshiba Global Commerce Solutions (Photo: Business Wire) “Europe is a dynamic market at the forefront of retail innovation, and home to many of our customers and partners,” said Poehler. “With our commitment to retail growth globally, Andrew, with his proven track-record and deep experience in technology solution development and business innovation, is exactly the right person to lead our drive to accelerate digital transformat
Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration17.1.2022 14:37:00 EET | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine. This long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious research capabilities of Imperial College London, aims to push the boundaries of allergic patient care by identifying biomarkers of AIT efficacy and expanding the knowledge of the pathophysiology of allergic diseases and their treatment with AIT. “We are thrilled about this collaboration with Imperial College London which will contribute to both deciphering the mode of action of AIT and identifying key markers that can be used in the routine practice of allergology for the benefit of patients and healthcare pra
Elliptic Launches Market Intelligence Unit and Announces New Proposition for Crypto Traders17.1.2022 14:10:00 EET | Press release
Elliptic, the leading provider of on-chain blockchain analytics, today announces the launch of its market intelligence unit; a second line of business for the organization that is focused on leveraging Elliptic’s best-in-class identity graph to build new propositions and use cases for businesses trading crypto. The new unit, led by Elliptic co-founder James Smith and Laura Coffey, will harness Elliptic’s dataset as an intrinsically valuable data layer for the burgeoning institutional crypto trading market. The data will provide access to the broadest asset coverage of on-chain identity metrics in the industry, allowing traders to: Forecast: Utilize real insights behind the movements of money to access fundamental activity metrics for a wide range of cryptoassets React: Profile the different types of actors behind deposits, withdrawals and other transactions in real-time to assess the motivations behind market-moving activity Analyze: Explore flows between businesses and other types of
38% of Supplier Survey Respondents Use Early Payment to Manage Working Capital, Up From 19% In 201717.1.2022 13:00:00 EET | Press release
38% of respondents take early payments monthly in 2021, up from 19% in 2017, according to a supplier sentiment survey conducted by Taulia, the leader in working capital technology solutions. Taulia’s global supplier sentiment survey has been conducted annually since 2017 and reflects the views of nearly 80,000 respondents over a five-year period. There has been growing interest from suppliers in regularly receiving early payment once an invoice is approved as an alternative source of finance. In 2021, one-fifth (22%) of suppliers were interested in receiving early payment every time for every customer, compared to 15% in 2017. The supplier's reasons for taking early payments varied. In 2021, the main reasons for their interest in early payments were*: Cash flow gap (49%) Collections/payment predictability (27%) Working capital needs (21%) Ease of use (18%) Reduce DSO (7%) There is also a clear progression towards better behaviour from businesses with a welcome decrease in late payment,
Gunma Prefecture's Geographical Indication “GI Tone-Numata” Sake Kicks Off Its Overseas Sales on January 17!17.1.2022 11:00:00 EET | Press release
Sake’s geographical indication, “GI Tone-Numata,” which consists of four sake breweries in the Tone-Numata area of Gunma Prefecture in Japan, requires that the breweries make the most of the local water and climate, and that the type of rice used as the raw material be one of the following: Yukihotaka, Gohyakumangoku, or Koshihikari. In addition, only yeast from the local area (Gunma KAZE yeast, Gunma G2 yeast, and brewer's house yeast) can be used, and vintage can be indicated under certain conditions, so only those that meet the extremely strict criteria are certified. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006144/en/ 7 types of GI Tone-Numata certified sake (Photo: Business Wire) According to Mr. Shinya Tasaki, Chairman of the Japan Sommelier Association, "GI Tone-Numata is equivalent to PDO in Europe or AOC in French wine and is expected to attract worldwide attention in the future." On January 17, "GI Tone
EcoFlow Launches the DELTA Pro, its Pioneering Portable Power Station, in Europe17.1.2022 10:00:00 EET | Press release
EcoFlow, a portable power and renewable energy solutions company, has launched the industry-leading DELTA Pro portable home battery in Europe. Originally a Kickstarter campaign, it smashed records to become the most-funded tech project at the time and still ranks sixth among all projects to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005003/en/ EcoFlow DELTA Pro Portable Home Battery (Photo: Business Wire) With a base capacity of 3.6kWh and expandable to 25kWh, the DELTA Pro is the industry’s first portable home battery and can provide multiple days’ worth of backup energy to families in the case of emergencies. In September 2021, EcoFlow launched the DELTA Max and the DELTA mini in Europe, both of which are designed to offer backup power for shorter blackout periods. “DELTA Pro’s highly successful Kickstarter campaign overwhelmingly demonstrates the consumer desire for portable clean energy power and storage
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom